---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-050796"
form_type: "8-K"
ticker: "ADCT"
cik: "0001771910"
company_name: "ADC Therapeutics SA"
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:31:30.381822+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ADC Therapeutics Q3 net product revenue $15.8M; net loss narrows to $41M; $60M PIPE strengthens cash

## Summary
- Q3 net product revenue $15.8M (down 12% YoY); nine-month 2025 revenue $51.2M vs $52.9M in 2024.
- Net loss $41.0M ($0.30 per share) vs $44.0M ($0.42) in Q3 2024; adjusted net loss $25.5M ($0.19).
- Completed $60M PIPE financing with $57.6M net proceeds; pro forma cash $292.3M to support ZYNLONTA expansion.
- LOTIS-7 updated data by end of 2025; LOTIS-5 topline data expected 1H 2026; FL IIT shows ORR 98.2%, CR 83.6%.
- IND-enabling for PSMA-targeting ADC to be completed by end of 2025; restructuring costs $13.5M YTD.

## SEC filing metadata
- accession: 0001628280-25-050796
- form_type: 8-K
- ticker: ADCT
- cik: 0001771910
- company_name: ADC Therapeutics SA
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1771910/000162828025050796/0001628280-25-050796-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1771910/000162828025050796/adc-20251110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-050796
- JSON: https://secwatch.observer/filing/0001628280-25-050796.json
- Plain text: https://secwatch.observer/filing/0001628280-25-050796.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.